Research location
Jersey City
New Jersey, United States
Advertisement
Research activity in Jersey City
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 60 trials and 61 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Jersey City
60 linked trials · page 1 of 2A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT07743450 · 2026-08-28 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation
RECRUITING
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation
RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-AdjustmentNCT07158164 · 2025-08-27 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation
RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedNCT05559164 · 2022-09-19 · 1 site observation
RECRUITING
ATATcH Alternating Treatment Plans for Advanced CancerNCT05358548 · 2022-04-28 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation TrialNCT07835555 · 2027-09-30 · 1 site observation
NOT_YET_RECRUITING
Pilot Trial of Preop Partial Radiation in Breast Cancer PatientsNCT07178665 · 2025-09-02 · 1 site observation
SUSPENDED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaNCT06664619 · 2024-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaNCT06261957 · 2024-05-31 · 1 site observation
COMPLETED
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast CancerNCT05949021 · 2023-10-07 · 1 site observation
ACTIVE_NOT_RECRUITING
G7 Dual Mobility With Vivacit-E or Longevity PMCFNCT05548972 · 2023-03-20 · 1 site observation
ENROLLING_BY_INVITATION
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.NCT05763121 · 2023-01-30 · 1 site observation
TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaNCT05748600 · 2023-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerNCT05198830 · 2022-12-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's DiseaseNCT05267535 · 2022-06-15 · 1 site observation
TERMINATED
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early StageNCT05333874 · 2022-04-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaNCT05097287 · 2021-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast CancerNCT04871516 · 2021-05-18 · 1 site observation
ACTIVE_NOT_RECRUITING
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)NCT04647214 · 2021-03-03 · 1 site observation
COMPLETED
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationNCT04456673 · 2020-07-06 · 1 site observation
COMPLETED
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.NCT02876900 · 2016-08-01 · 1 site observation
COMPLETED
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesNCT01831765 · 2013-08-26 · 1 site observation
COMPLETED
Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension TreatmentNCT01758263 · 2012-10-01 · 1 site observation
UNKNOWN
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of AsthmaNCT01720069 · 2012-10-01 · 1 site observation
COMPLETED
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 DiabetesNCT00399711 · 2006-11-01 · 1 site observation
COMPLETED
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesNCT00229658 · 2005-09-01 · 1 site observation
COMPLETED
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)NCT00334906 · 2005-07-01 · 1 site observation
COMPLETED
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 DiabetesNCT00141492 · 2004-10-01 · 1 site observation
COMPLETED
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00091663 · 2004-08-01 · 1 site observation
COMPLETED
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)NCT00094367 · 2004-07-01 · 2 site observations
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.